| Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session |
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday. |
benzinga.com |
2025-05-14 12:13:11 |
Czytaj oryginał (ang.) |
| GRAIL, Inc. (GRAL) Q1 2025 Earnings Call Transcript |
GRAIL, Inc. (NASDAQ:GRAL ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Bob Ragusa - CEO Aaron Freidin - CFO Joshua Ofman - President Harpal Kumar - President, International Business and BioPharma Andy Partridge - Chief Commercial Officer Conference Call Participants Subbu Nabi - Guggenheim Partners Tejas Savant - Morgan Stanley Doug Schenkel - Wolfe Research Kyle Mikson - Canaccord Operator Good day, ladies and gentlemen. And welcome to the GRAIL First Quarter 2025 Earnings Call. |
seekingalpha.com |
2025-05-13 23:16:05 |
Czytaj oryginał (ang.) |
| GRAIL Reports First Quarter 2025 Financial Results |
Q1 U.S. Galleri Revenue Grew 22% Year-Over-Year to $28.7 Million GRAIL Announces Positive Top-Line Results From the Prevalent Screening Round of the NHS-Galleri Trial Cash Position of $677.9 Million Provides Runway Into 2028 MENLO PARK, Calif. , May 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter 2025. |
prnewswire.com |
2025-05-13 20:01:00 |
Czytaj oryginał (ang.) |
| GRAIL and athenahealth Team Up to Offer Healthcare Providers Streamlined Ordering of GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test |
MENLO PARK, Calif. , May 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a new partnership with athenahealth, a leading provider of network-enabled software and services for healthcare practices and systems nationwide. |
prnewswire.com |
2025-05-12 20:01:00 |
Czytaj oryginał (ang.) |
| GRAIL to Announce First Quarter 2025 Financial Results |
MENLO PARK, Calif. , April 29, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the first quarter 2025 following the close of market on Tuesday, May 13, 2025. |
prnewswire.com |
2025-04-29 20:01:00 |
Czytaj oryginał (ang.) |
| GRAIL to Present New Data on Galleri® and its Methylation Platform at American Association for Cancer Research (AACR) Annual Meeting |
Real-World Data in 100,000 Patients Further Support the Galleri® Test's Ability to Simultaneously Screen for Multiple Cancers, as Well as its Accuracy of Cancer Signal of Origin Prediction to Support More Efficient Diagnostic Evaluations Data From GRAIL's ctDNA-based Targeted Methylation Assay Highlight Potential to Identify Robust Signals of Promoter Methylation MENLO PARK, Calif. , April 22, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present new data highlighting the latest real-world evidence with the Galleri® multi-cancer early detection (MCED) test and additional data from GRAIL's circulating tumor DNA (ctDNA)-based targeted methylation platform at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 25-30, 2025. |
prnewswire.com |
2025-04-22 20:01:00 |
Czytaj oryginał (ang.) |
| This Cancer Test Could Become Routine—and a Big Seller, Says Analyst |
Grail stock will increase at least 20% over the next year, projects Canaccord's Kyle Gibson. |
barrons.com |
2025-04-21 20:47:00 |
Czytaj oryginał (ang.) |
| GRAIL's Galleri Progresses While Back In Accumulation Levels |
GRAL's Galleri test is easily its main value driver at this point. This test can screen over 50 cancers with high sensitivity and accuracy. Post-spin-off from Illumina, GRAL has continued growing its revenues while also securing partnerships like Quest Diagnostics and TRICARE. GRAL's Galleri also secured the FDA's Breakthrough Device status, and its pivotal PMA submission should happen by 1H2026. |
seekingalpha.com |
2025-04-12 13:32:28 |
Czytaj oryginał (ang.) |
| How Does GRAIL Benefit From The Proposed MCED Legislation? |
GRAIL, Inc.'s Galleri test could see significant revenue growth if the bipartisan MCED bill passes, enabling Medicare reimbursement for FDA-approved multi-cancer early detection tests. Galleri's potential market includes 67 million Medicare beneficiaries, with a conservative estimate of $2.4 billion in revenue by the fifth year post-legislation. Despite promising financials and market leadership, Galleri's FDA approval is pending, and Medicare reimbursement may not start until 2028, posing short-term risks. |
seekingalpha.com |
2025-04-08 13:49:58 |
Czytaj oryginał (ang.) |
| GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
MENLO PARK, Calif. , Feb. 26, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 108,450 shares of GRAIL's common stock to 15 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. |
prnewswire.com |
2025-02-26 18:05:00 |
Czytaj oryginał (ang.) |
| GRAIL Partners With Actress Kate Walsh for Generation Possible to Raise Awareness of Multi-Cancer Early Detection Testing |
MENLO PARK, Calif. , Feb. 25, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, has partnered with award-winning actress Kate Walsh to launch Generation Possible, an educational initiative to raise awareness of multi-cancer early detection (MCED) testing. |
prnewswire.com |
2025-02-25 11:00:00 |
Czytaj oryginał (ang.) |
| GRAIL to Present at TD Cowen 45th Annual Health Care Conference |
MENLO PARK, Calif. , Feb. 21, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the TD Cowen 45th Annual Health Care Conference in Boston on Tuesday, Mar. 4 at 9:10 a.m. |
prnewswire.com |
2025-02-21 11:00:00 |
Czytaj oryginał (ang.) |
| GRAIL, Inc. (GRAL) Q4 2024 Earnings Call Transcript |
GRAIL, Inc. (NASDAQ:GRAL ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Bob Ragusa - Chief Executive Officer and Board Member Aaron Freidin - Chief Financial Officer Joshua Ofman - President Sir Harpal Kumar - President of International Business and BioPharma Conference Call Participants Doug Schenkel - Wolfe Research Operator Good day, ladies and gentlemen, and welcome to the GRAIL Fourth Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode. |
seekingalpha.com |
2025-02-21 00:09:03 |
Czytaj oryginał (ang.) |
| GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results |
Sold More than 137,000 Galleri® Tests in 2024, Growing U.S. Galleri Revenue 45% Year-Over-Year to $108.6 Million Completed Study Visits for Two Registrational Studies in July to Support Modular PMA Submission for Galleri On Track for Continued Commercial Growth in 2025 with TRICARE Coverage and Recent Announcement of Quest Integration Moderated Cash Burn, Ending 2024 with a Cash Position of $767M, Extending Runway into 2028 MENLO PARK, Calif. , Feb. 20, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2024 and provided business updates. |
prnewswire.com |
2025-02-20 18:02:00 |
Czytaj oryginał (ang.) |
| GRAIL to Announce Fourth Quarter 2024 Financial Results |
MENLO PARK, Calif. , Feb. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter 2024 following the close of market on Thursday, Feb. 20, 2025. |
prnewswire.com |
2025-02-12 18:02:00 |
Czytaj oryginał (ang.) |
| GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System |
GRAIL's Galleri Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience MENLO PARK, Calif. and SECAUCUS, N.J. |
prnewswire.com |
2025-02-12 11:00:00 |
Czytaj oryginał (ang.) |
| Watch These Grail Price Levels After Med Tech Company's Stock Soared 64% Last Week |
Grail (GRAL) shares could remain in focus after surging to a new record high on Friday to cap off a huge week of gains amid optimism about the medical technology company's early-detection cancer screening blood tests. |
investopedia.com |
2025-01-27 02:05:39 |
Czytaj oryginał (ang.) |
| Early Cancer Detection Firm Grail Leads Nasdaq Gainers as Stock Jumps 20% |
Shares of Grail, Inc. (GRAL) surged 20% intraday Wednesday, putting the medical technology company above the likes of Arm Holdings (ARM) and Netflix (NFLX) to be the biggest gainer in the Nasdaq 100 index in recent trading. |
investopedia.com |
2025-01-22 15:01:35 |
Czytaj oryginał (ang.) |
| Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology |
Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection Testing MENLO PARK, Calif. , Jan. 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that patient-reported outcomes (PRO) assessing patient perspectives from the PATHFINDER study were published in Lancet Oncology. |
prnewswire.com |
2025-01-13 20:49:00 |
Czytaj oryginał (ang.) |
| GRAIL to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
MENLO PARK, Calif. , Dec. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 43rd Annual J.P. |
prnewswire.com |
2024-12-18 18:01:00 |
Czytaj oryginał (ang.) |
| GRAIL: Biotech Stock Targeting $100B Cancer Market |
GRAIL NASDAQ: GRAL is a small-cap biotechnology company that has gone on a very strong run over the last month and a half. Shares of the healthcare stock are up 58% since Oct. 24, as of the Dec. 11 close. |
marketbeat.com |
2024-12-14 09:00:09 |
Czytaj oryginał (ang.) |
| World's biggest hedge fund flags the ‘holy grail' that may shield investors if U.S. stock rally crumbles |
Karen Karniol-Tambour, co-chief investment officer at Bridgewater Associates, says valuations are much higher for U.S. stocks than they were when the bull run began. |
marketwatch.com |
2024-12-05 07:46:00 |
Czytaj oryginał (ang.) |
| GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
MENLO PARK, Calif. , Dec. 3, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 115,093 shares of GRAIL's common stock to 46 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. |
prnewswire.com |
2024-12-03 18:01:00 |
Czytaj oryginał (ang.) |
| GRAIL to Participate in Upcoming Investor Conferences |
MENLO PARK, Calif. , Nov. 19, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will participate in the following investor conferences. |
prnewswire.com |
2024-11-19 18:05:00 |
Czytaj oryginał (ang.) |
| GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study |
MENLO PARK, Calif. , Nov. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC. |
prnewswire.com |
2024-11-18 18:01:00 |
Czytaj oryginał (ang.) |
| GRAIL Inc. (GRAL) Q3 2024 Earnings Call Transcript |
GRAIL Inc. (NASDAQ:GRAL ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Robert Ragusa - CEO & Director Aaron Freidin - Chief Financial Officer Joshua Ofman - President Harpal Kumar - President, International Business and BioPharma Conference Call Participants Operator Good day, ladies and gentlemen, and welcome to the GRAIL Third Quarter 2024 Earnings Call. [Operator Instructions] Please be advised that this conference call is being recorded. |
seekingalpha.com |
2024-11-15 06:18:20 |
Czytaj oryginał (ang.) |
| GRAIL Reports Third Quarter 2024 Financial Results |
Galleri Revenue Grew 52% Year-Over-Year to $25.4 Million Commercial Galleri Sales Surpassed 250,000 Tests Since Launch Cash Balance of $853.6 Million Provides Runway Into 2028 MENLO PARK, Calif. , Nov. 12, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter 2024. |
prnewswire.com |
2024-11-12 18:06:00 |
Czytaj oryginał (ang.) |
| GRAIL to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum |
MENLO PARK, Calif. , Nov. 4, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, Nov. 21 at 11:00 a.m. |
prnewswire.com |
2024-11-04 18:01:00 |
Czytaj oryginał (ang.) |
| GRAIL to Announce Third Quarter 2024 Financial Results |
MENLO PARK, Calif. , Oct. 29, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2024 following the close of market on Tuesday, Nov. 12, 2024. |
prnewswire.com |
2024-10-29 18:01:00 |
Czytaj oryginał (ang.) |
| Google: The Bullish Pivot Before The Earnings Grail |
My previous bearish call on Google has aged well, with the stock losing around 14% of its value since July 10. I still believe that Google struggles to compete in the generative AI space, but this does not spell the end for the company. The stock appears to be a compelling opportunity ahead of the Q3 earnings release, supported by a strong mix of catalysts. |
seekingalpha.com |
2024-10-27 13:00:00 |
Czytaj oryginał (ang.) |
| GRAIL Presents Initial Results From REFLECTION Real-World Evidence Study of Galleri® Multi-Cancer Early Detection (MCED) Test at the Early Detection of Cancer Conference |
Study Participants from Veteran Affairs Sites Include a Diverse Population With Toxic Exposure MENLO PARK, Calif. , Oct. 23, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced early results from the REFLECTION study, which aims to understand the real-world experience of the Galleri® multi-cancer early detection (MCED) test in routine clinical settings. |
prnewswire.com |
2024-10-23 22:00:00 |
Czytaj oryginał (ang.) |
| GRAIL Appoints Sarah Krevans to Board of Directors |
MENLO PARK, Calif. , Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. |
prnewswire.com |
2024-10-21 20:01:00 |
Czytaj oryginał (ang.) |
| Insider Buying Slows, but Not for 7 These Buyers |
24/7 Wall St. Insights Insider buying slowed to a trickle ahead of the third-quarter earnings reporting season. |
247wallst.com |
2024-10-13 13:45:27 |
Czytaj oryginał (ang.) |
| Stock Picks From Seeking Alpha's September 2024 New Analysts |
In September, thirty new analysts joined Seeking Alpha, offering diverse stock picks and insights, from Strong Buy to Strong Sell ratings. Highlighted picks include InMode Ltd., Intel Corporation, and iShares 20+ Year Treasury Bond ETF, each with unique investment theses and strong buy ratings. Analysts' backgrounds range from software engineering to finance, enhancing their stock research with diverse perspectives and methodologies. |
seekingalpha.com |
2024-10-04 12:00:00 |
Czytaj oryginał (ang.) |
| Vieu cracks the “holy grail” of B2B sales with AI-powered business network; raises $11m as growth scales |
Vieu's AI-powered Sales Graph challenges traditional social networks and CRM systems to fast-track enterprise sales pursuits. The Vieu Graph platform indexes billions of relationships and industry-specific data sets to reveal deep social connections and account intelligence that helps build trust with the customer from the first touchpoint. Vieu's AI-powered Sales Graph challenges traditional social networks and CRM systems to fast-track enterprise sales pursuits. The Vieu Graph platform indexes billions of relationships and industry-specific data sets to reveal deep social connections and account intelligence that helps build trust with the customer from the first touchpoint. |
globenewswire.com |
2024-10-03 16:30:00 |
Czytaj oryginał (ang.) |
| GRAIL: Post-Spinoff, Illumina Maintains Control And Incentive To Support Success |
GRAIL Inc., spun off from Illumina Inc. in June 2024, faces financial challenges but holds significant growth potential with its Galleri cancer-screening test. Despite a strong balance sheet, GRAIL's Q2 2024 operational loss was $1.64 billion, primarily due to non-cash goodwill and intangible impairments. GRAIL's restructuring plan aims to cut costs, focus on Galleri sales, and extend its cash runway to 2028, supported by Illumina's continued involvement. |
seekingalpha.com |
2024-09-24 16:41:49 |
Czytaj oryginał (ang.) |
| GRAIL's Potential Turnaround: Seeking FDA Approval For Galleri |
Grail's Galleri test detects over 50 cancer types early, potentially saving lives, and is progressing towards FDA approval and broader insurance coverage. The company, a spinoff from Illumina, has significant backing and aims to reduce costs while expanding its market presence and regulatory validation. Despite high cash burn, Grail's strong cash reserves and strategic focus on FDA approval and Medicare reimbursement present substantial upside potential. |
seekingalpha.com |
2024-09-09 13:16:27 |
Czytaj oryginał (ang.) |
| EU top court backs Illumina fight against EU probe into Grail deal |
Europe's top court on Tuesday backed U.S. gene sequencing company Illumina's fight against EU antitrust regulators' investigation into its $7.1 billion bid for cancer diagnostic test maker Grail. |
reuters.com |
2024-09-03 07:50:53 |
Czytaj oryginał (ang.) |
| GRAIL ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4) |
MENLO PARK, Calif. , Aug. 30, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 182,223 shares of GRAIL's common stock to 55 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. |
prnewswire.com |
2024-08-30 21:55:00 |
Czytaj oryginał (ang.) |